• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email
    SC 13G/A 1 tm2427858d5_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)

     

    Krystal Biotech, Inc.

    (Name of Issuer)
     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    501147102
    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 501147102

     

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    810,245 (1) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    810,245 (1) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    810,245 (1) 

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    2.8% (2) 

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 810,245 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 28,729,950 shares of Common Stock outstanding as of July 29, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 5, 2024 (the “Form 10-Q”).

     

     

     

     

    CUSIP No. 501147102

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    810,245 (3) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    810,245 (3) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    810,245 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    2.8% (4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 810,245 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 28,729,950 shares of Common Stock outstanding as of July 29, 2024, as reported by the Issuer in the Form 10-Q.

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Krystal Biotech, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    2100 Wharton Street, Suite 701

    Pittsburgh, Pennsylvania 15203

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.00001 par value

     

    (e)CUSIP Number

     

    501147102

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

     

     

     

    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 810,245 (1)
    Jeremy C. Green – 810,245 (1)

     

    (b)Percent of class:

     

    Redmile Group, LLC – 2.8% (2)
    Jeremy C. Green – 2.8% (2)

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    810,245 (1)

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    810,245 (1)

     

     

     

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    810,245 (1)

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    810,245 (1)

     

    (1)Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 810,245 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (2)Percentage based on 28,729,950 shares of Common Stock outstanding as of July 29, 2024, as reported by the Issuer in the Form 10-Q.

      

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9.Notice of Dissolution of Group.

     

    N/A.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

     

    Redmile Group, LLC

         
      By: /s/ Jeremy C. Green
       

    Name: Jeremy C. Green

    Title: Managing Member

     

        /s/ Jeremy C. Green
       

    Jeremy C. Green

     

     

     

    Get the next $KRYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    2/28/2023$79.00 → $124.00Neutral → Buy
    Goldman
    More analyst ratings

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

      PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology co

      5/7/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

      VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. "We were thrilled to receive VYJUVEK approval in Europe, and with the p

      5/6/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

      VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the geneti

      4/28/25 7:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, R&D Krishnan Suma sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,463,711 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:06:28 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Krishnan Krish S sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,533,056 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:04:23 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Romano Kathryn covered exercise/tax liability with 8,054 shares, sold $131,415 worth of shares (750 units at $175.22) and converted options into 12,500 shares, increasing direct ownership by 24% to 19,318 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      2/28/25 7:01:45 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Financials

    Live finance-specific insights

    See more
    • Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

      VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. "We were thrilled to receive VYJUVEK approval in Europe, and with the p

      5/6/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

      PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52291. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of th

      4/17/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

      Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, ending the quarter with $749.6 million in cash and investments PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update. "Last year, our commercial and financial strength allowed us to deliver significant earnings growth, continue to build out a glob

      2/19/25 7:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

      SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

      11/14/24 9:00:58 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

      SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

      11/12/24 10:32:12 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Krystal Biotech Inc.

      SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

      10/16/24 12:28:49 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    SEC Filings

    See more
    • Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:09:31 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Krystal Biotech Inc.

      10-Q - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:08:58 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      4/28/25 8:53:15 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Leadership Updates

    Live Leadership Updates

    See more

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

      PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

      4/7/25 4:30:00 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

      PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my

      1/14/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology
    • Jefferies initiated coverage on Krystal Biotech with a new price target

      Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

      3/5/25 7:35:58 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech downgraded by Citigroup with a new price target

      Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

      8/6/24 8:53:09 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Krystal Biotech with a new price target

      Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00

      11/20/23 7:47:05 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

      For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

      5/19/23 1:48:20 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care